Aminopyridine compounds and methods for the preparation and use thereof

1. A compound according to Formula I:

or a pharmaceutically acceptable salt thereof, wherein

W is selected from the group consisting of a bond, CH 2 , and O;

R 1a and R 1b are independently selected from the group consisting of H and C 1-6 alkyl;

R 2 is selected from the group consisting of C 1-6 alkyl and halogen;

subscript n is 0 or 1;

R 3 is selected from the group consisting of C 3-8 cycloalkyl, C 3-8 alkyl,

C 3-12 heterocyclyl, C 6-10 aryl, and C 5-12 heteroaryl wherein R 3 is optionally substituted with one or more R 3a substituents;

each R 3a is independently selected from the group consisting of halogen, —CN, —NO 2 , —N 3 , —OH, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy,

C 1-4 haloalkoxy, —N(R c ) 2 , —(CH 2 ) k C(O)R b ,—NR c (CH 2 ) u C(O)R b , —O(CH 2 ) u C(O)R b , —(CH 2 ) k CONR c R c , —(CH 2 ) k NR c C(O)R b , —NR c (CH 2 ) u CONR c R c , —NR c (CH 2 ) u NR c C—(O)R b , —O(CH 2 ) u CONR c R c , and —O(CH 2 ) u NR c C(O)R b , and optionally substituted triazolyl;

each R b is independently selected from the group consisting of C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 deuteroalkyl;

each R c is independently selected from the group consisting of hydrogen and C 1-8 alkyl;

each subscript k is independently selected from 0, 1, 2, 3, 4, 5, and 6;

each subscript u is independently selected from 1, 2, 3, 4, 5, and 6;

R 4 is selected from the group consisting of —CH 2 R 4a and C 1-6 haloalkyl;

R 4a is selected from the group consisting of —O—R 5 , —S—R 6 , —SO—R 6 , —SO 2 —R 6 , —N(R 7 ) 2 , and C 5-12 heteroaryl;

R 5 is selected from the group consisting of phenyl, C 1-6 alkyl, C 1-6 haloalkyl, and

C 5-12 heteroaryl, wherein phenyl is substituted with 1-5 halogens, and wherein

C 5-12 heteroaryl is optionally substituted with halogen or C 1-3 haloalkyl;

R 6 is selected from the group consisting of phenyl, C 1-6 alkyl, C 1-6 haloalkyl, and

C 5-12 heteroaryl, wherein phenyl is optionally substituted with 1-5 halogens, and

wherein C 5-12 heteroaryl is optionally substituted with halogen or C 1-3 haloalkyl; and

each R 7 is independently selected C 1-6 alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, having a structure according to Formula IIa:

or

a structure according to Formula IIb:

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of C 3-8 cycloalkyl and C 3-8 alkyl, each of which is optionally substituted with one or more R 3a substituents.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is —CH 2 —O—R 5 and wherein R 5 is phenyl substituted with 1-5 halogens.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is —CH 2 —O—R 5 and R 5 is selected from the group consisting of 1,1,1,3,3,3-hexafluoroprop-2-yl, isoxazolyl, and phenyl, wherein phenyl is substituted with 1-5 halogens.

6. The compound of claim 1 , which is selected from the group consisting of

and pharmaceutically acceptable salts thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8. A compound according to Formula III:

or a pharmaceutically acceptable salt thereof, wherein:

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-8 cycloalkyl;

R 12a and R 12b are independently selected from the group consisting of H, C 1-6 alkyl, and

C 6-10 aryl, or

R 12a and R 12b are taken together to form C 3-6 cycloalkyl, or

R 12a and R 12b are taken together to form 4- to 10-membered heterocyclyl which is optionally substituted with one or more R 17 ;

each R 13a and each R 13b is independently selected from the group consisting of H, —OH, and C 1-6 alkyl, or

one R 13a and R 11 are taken together to form 4- to 10-membered heterocyclyl, or

one R 13b and R 12b are taken together to form a 5- or 6-membered ring;

R 14 is selected from the group consisting of H and halogen, or

R 14 , R 12a , and R 12b are taken together to form a 6- to 8-membered ring, which is optionally substituted with one or more R 18 , or

R 14 and one R 13a are taken together to form a 5- to 8-membered ring, which is optionally substituted with one or more R 18 , or

R 14 is taken together with one R 13a and one R 13b on the same carbon atom to form a 5- to 8-membered ring, which is optionally substituted with one or more R 18 , or

R 14 , R 11 , and R 12a are taken together to form a 6- to 10-membered bicyclic ring, which is optionally substituted with one or more R 18 ;

R 15a and R 15b are independently selected from the group consisting of H and C 1-6 alkyl;

R 16 is independently selected from the group consisting of C 1-6 alkyl and halogen;

each R 17 is independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy,

C 1-6 haloalkyl, C 1-6 haloalkoxy, —OH, and —N(R 17a ) 2 , wherein each R 17a is independently selected from the group consisting of H and C 1-6 alkyl;

each R 18 is independently selected from the group consisting of C 1-6 alkyl and halogen;

Y is selected from the group consisting of O, S, C(R 19a ) 2 , and NR 19b ;

each R 19a is selected from the group consisting of H and C 1-6 alkyl, or

one R 19a and one R 13b on adjacent atoms are taken together to form a double bond;

R 19b is selected from the group consisting of H and C 1-6 alkyl, or

R 19b and R 11 are taken together to form a 4- to 6-membered ring;

subscript m is 0, 1, 2, or 3; and

subscript q is 0 or 1.

9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, having a structure according to Formula IVa:

10. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, having a structure according to Formula V:

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein Y is NR 19b .

12. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 12a and R 11 are taken together to form 4- to 10-membered heterocyclyl.

13. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 12a is H and R 12b is selected from the group consisting of H, C 1-6 alkyl, and C 6-10 aryl.

14. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 15a and R 15b are H.

15. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein subscript q is 0.

16. The compound of claim 8 , which is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

17. The compound of claim 8 , which is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

18. The compound of claim 8 , which is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

19. A method of treating a disease or condition associated with P. gingivalis infection, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

20. The method of claim 19 , wherein the disease or condition is selected from the group consisting of a brain disorder, periodontal disease, diabetes, a cardiovascular disease, arthritis, rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis, elevated risk of preterm birth, pneumonia, cancer, a kidney disease, a liver disease, a retinal disorder, and glaucoma.

21. The method of claim 20 , wherein the brain disorder is selected from the group consisting of Alzheimer's disease, Down's syndrome, epilepsy, autism, Parkinson's disease, essential tremor, fronto-temporal dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, mild cognitive impairment, age associated memory impairment, chronic traumatic encephalopathy, stroke, cerebrovascular disease, Lewy Body disease, multiple system atrophy, schizophrenia, and depression.

22. The method of claim 21 , wherein the brain disorder is Alzheimer's disease.

23. The method of claim 22 , further comprising administering to the subject one or more active agents selected from the group consisting of a cholinesterase inhibitor, a serotonin modulator, an NMDA modulator, an Aβ targeted therapy, an ApoE targeted therapy, a microglia targeted therapy, a blood brain barrier targeted therapy, a tau targeted therapy, a complement targeted therapy, and an anti-inflammatory.